Intra-host diversity of hepatitis E virus polymerase during sofosbuvir treatment

Hepatitis E virus infections remain a serious problem in immunocompromised patients, leading to chronic infections in about 50% of cases. Off-label use of Ribavirin is the only treatment option because no HEV-specific antivirals are available. Recently, the hepatitis C virus polymerase inhibitor Sofosbuvir was evaluated as a potential antiviral against HEV during a 24-week Sofosbuvir multicenter phase II pilot trial in nine patients (Cornberg et al. 2020).